Jefferies Reiterates Buy Rating on Vera Therapeutics (VERA)

June 2, 2026 3:56 PM

Jefferies analyst Farzin Haque reiterated a Buy rating and $60.00 price target on Vera Therapeutics (NASDAQ: VERA).The analyst comments "VERA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found